Title |
Diroximel Fumarate Demonstrates an Improved Gastrointestinal Tolerability Profile Compared with Dimethyl Fumarate in Patients with Relapsing–Remitting Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III EVOLVE-MS-2 Study |
|---|---|
Involved |
The EVOLVE-MS-2 Study Group (Verfasser)
Robert T. Naismith (Verfasser) Annette Wundes (Verfasser) Tjalf Ziemssen (Verfasser)
Elzbieta Jasinska (Verfasser)
Mark S. Freedman (Verfasser) Anthony J. Lembo (Verfasser) Krzysztof Selmaj (Verfasser) Ilda Bidollari (Verfasser) Hailu Chen (Verfasser) Jerome Hanna (Verfasser) Richard Leigh-Pemberton (Verfasser) Maria Lopez-Bresnahan (Verfasser) Jennifer Lyons (Verfasser) Catherine Miller (Verfasser) David Rezendes (Verfasser) Jerry S. Wolinsky (Verfasser) SpringerLink (Online service) (Sonstige) |
Published in |
CNS drugs : evaluations of drug therapy in the management of psychiatric and neurological disease 34, 2, 17.1.2020, date:2.2020, Seite 185-196 |
Published |
2020 |
Language |
|
Country |
|
Topic |
|
Subject |
Neurology. |
DDC notation |
|
Persistent identifier |
urn:nbn:de:101:1-2020051202232844385133 (URN) |
Record ID |
1209946882 |
Please note
The beta version does not yet contain all functions and information of the DNB portal catalogue. If you are missing information or want to order a medium, please visit the page in the DNB portal catalogue via the following link: